首页> 外国专利> Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof

Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof

机译:用于诱导体细胞直接转分化为血管祖细胞的组合物及其用途

摘要

The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell, a pharmaceutical composition for the prevention or treatment of ischemic vascular diseases, a cell therapeutic agent for the prevention or treatment of ischemic vascular diseases, a composition for screening a therapeutic drug for ischemic vascular diseases, a 3D printing biological material composition for the production of an artificial tissue for the treatment of ischemic vascular diseases, and a method for direct transdifferentiation of a somatic cell into a vascular progenitor cell. By producing a vascular progenitor cell by direct transdifferentiation of a somatic cell according to the present invention, it is possible to reduce the production period of the vascular progenitor cell and to avoid the formation of teratoma, which is a side effect of an induced pluripotent stem cell, thereby minimizing the side effects of a stem cell therapeutic agent.
机译:本发明涉及用于诱导体细胞直接转分化为血管祖细胞的组合物及其用途,更具体地说,涉及用于诱导体细胞直接转分化为血管祖细胞的组合物,用于药物的药物组合物。预防或治疗缺血性血管疾病,用于预防或治疗缺血性血管疾病的细胞治疗剂,用于筛选治疗性缺血性血管疾病的治疗药物的组合物,用于为该组织生产人造组织的3D打印生物材料组合物治疗缺血性血管疾病,以及将体细胞直接转分化为血管祖细胞的方法。通过根据本发明通过体细胞的直接转分化产生血管祖细胞,可以减少血管祖细胞的产生时间并避免畸胎瘤的形成,这是诱导的多能干的副作用。细胞,从而使干细胞治疗剂的副作用最小化。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号